Metapharm is a company whose goal is to ensure the shortest approval of regulatory processes to ensure the most efficient market access, distribution and commercialization of various off-patent small molecules and biosimilars, becoming a reliable biosimilar/generic manufacturer's partner in Poland, Lithuania, Latvia and Estonia. We are dedicated to provide off-patent specific, targeted drugs for the patients in Lithuania, Latvia and Estonia and Poland. Metapharm has developed a dependable commercialization excellence platform to accelerate access to off-patent specific, targeted drugs, allowing governments to save resources for new innovative therapies. Our local experience led us to identify gaps in the adoption of certain specialty molecules in the region markets, which if eradicated, could alleviate the financial burden of the government to a good extent and ultimately result in improved implementation of health technology innovations, saving patients' lives and easing access to medicines